HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Antineoplastic effectiveness and toxicity of idarubicin (4-demethoxy-daunorubicin) in recurrent acute leukemias in childhood].

Abstract
11 patients with refractory acute leukemia of childhood were treated with idarubicin per os. Bone marrow toxicity which was observed at a dose level of 60 mg/m2 p.o. (3 x 20 mg q 24 hrs p.o.) per 3 weeks was found to be the dose limiting factor. In contrast to the first phase I study of Tan et al. (16) the maximal tolerated dose in the present study was found to be lower at a level of 90 mg/m2 p.o. (3 x 30 mg/m2 p.o. q 24 hrs) per 3 weeks. Therefore, we recommend a dosage of 60 mg/m2 p.o. (3 x 20 mg/m2 p.o. q 24 hrs) per 3 weeks as a starting dose for phase II/III studies. 2 out of the 11 anthracycline pretreated patients (91-880 mg/m2) with acute leukemia reached a complete remission undergoing idarubicin p.o. as a single therapy.
AuthorsR Erttmann, U Bode, N Erb, P Forcadell de Dios, P Gutjahr, R Haas, N Kuhn, H Siewert, G Landbeck
JournalKlinische Padiatrie (Klin Padiatr) 1988 May-Jun Vol. 200 Issue 3 Pg. 200-4 ISSN: 0300-8630 [Print] Germany
Vernacular TitleAntineoplastische Wirksamkeit und Toxizität von Idarubicin (4-Demethoxydaunorubicin) bei rezidivierten akuten Leukämien des Kindesalters.
PMID3062256 (Publication Type: Clinical Trial, English Abstract, Journal Article)
Chemical References
  • Antibiotics, Antineoplastic
  • Idarubicin
Topics
  • Adolescent
  • Antibiotics, Antineoplastic (adverse effects, therapeutic use)
  • Bone Marrow (drug effects)
  • Child
  • Child, Preschool
  • Clinical Trials as Topic
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Female
  • Humans
  • Idarubicin (adverse effects, therapeutic use)
  • Leukemia, Lymphoid (drug therapy)
  • Leukemia, Myeloid, Acute (drug therapy)
  • Leukocyte Count (drug effects)
  • Male
  • Remission Induction

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: